Cantor Fitzgerald Starts Phathom Pharmaceuticals (PHAT) at Overweight
Tweet
Share
E-mailGet Alerts PHAT Hot Sheet
Price: $9.44 +1.72%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Join SI Premium – FREE
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Overweight rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.
Shares of Phathom Pharmaceuticals closed at $5.62 yesterday.
You May Also Be Interested In
- B.Riley Starts Weave Communications Inc (WEAV) at Buy
- Leerink Starts Scribe Therapeutics Inc (SCTX) at Outperform
- Evercore ISI Starts Equity Residential (EQR) at In Line
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
